NASDAQ:EXEL
$17.47
(
-1.36%
)
Friday, 27th Jan 2023
Exelixis Stock Price (Quote)
| Range | Low Price | High Price | Comment |
|---|---|---|---|
| 30 days | $15.36 | $17.80 | Friday, 27th Jan 2023 EXEL stock ended at $17.47. This is 1.36% less than the trading day before Thursday, 26th Jan 2023. During the day the stock fluctuated 1.92% from a day low at $17.47 to a day high of $17.80. |
| 90 days | $15.32 | $17.80 | |
| 52 weeks | $14.87 | $23.40 |
Historical Exelixis prices
| Date | Open | High | Low | Close | Volume |
| 2023-01-27 | $17.70 | $17.80 | $17.47 | $17.47 | 1 597 849 |
| 2023-01-26 | $17.64 | $17.80 | $17.46 | $17.71 | 2 081 484 |
| 2023-01-25 | $17.28 | $17.37 | $17.00 | $17.33 | 2 384 848 |
| 2023-01-24 | $17.03 | $17.60 | $17.00 | $17.36 | 3 673 054 |
| 2023-01-23 | $16.71 | $17.03 | $16.56 | $17.02 | 5 460 621 |
| 2023-01-20 | $16.64 | $16.85 | $16.36 | $16.73 | 7 944 546 |
| 2023-01-19 | $16.32 | $16.61 | $16.31 | $16.53 | 2 951 500 |
| 2023-01-18 | $16.33 | $16.53 | $16.29 | $16.30 | 2 550 888 |
| 2023-01-17 | $16.41 | $16.50 | $16.21 | $16.32 | 2 025 600 |
| 2023-01-13 | $16.60 | $16.86 | $16.16 | $16.43 | 2 452 327 |
| 2023-01-12 | $16.71 | $16.72 | $16.40 | $16.69 | 2 900 619 |
| 2023-01-11 | $17.09 | $17.09 | $16.63 | $16.79 | 1 990 022 |
| 2023-01-10 | $16.82 | $17.18 | $16.79 | $17.17 | 2 444 200 |
| 2023-01-09 | $17.23 | $17.34 | $16.54 | $16.85 | 4 140 658 |
| 2023-01-06 | $16.69 | $17.65 | $16.66 | $17.27 | 2 632 100 |
| 2023-01-05 | $16.92 | $17.00 | $16.46 | $16.59 | 3 109 169 |
| 2023-01-04 | $16.41 | $17.07 | $16.40 | $17.03 | 2 532 441 |
| 2023-01-03 | $16.03 | $16.40 | $16.03 | $16.30 | 2 373 247 |
| 2022-12-30 | $15.61 | $16.07 | $15.58 | $16.04 | 2 201 654 |
| 2022-12-29 | $15.48 | $15.78 | $15.36 | $15.66 | 1 797 626 |
| 2022-12-28 | $15.49 | $15.70 | $15.41 | $15.41 | 1 159 933 |
| 2022-12-27 | $15.80 | $15.84 | $15.48 | $15.48 | 1 384 304 |
| 2022-12-23 | $15.88 | $16.02 | $15.71 | $15.83 | 1 558 318 |
| 2022-12-22 | $15.70 | $15.92 | $15.57 | $15.89 | 1 661 236 |
| 2022-12-21 | $15.73 | $15.91 | $15.62 | $15.76 | 1 739 851 |
| 2022-12-20 | $15.39 | $15.77 | $15.39 | $15.69 | 1 606 162 |
| 2022-12-19 | $15.98 | $16.06 | $15.32 | $15.44 | 2 683 180 |
| 2022-12-16 | $15.73 | $15.99 | $15.56 | $15.94 | 7 305 539 |
| 2022-12-15 | $16.08 | $16.14 | $15.71 | $15.80 | 2 052 206 |
| 2022-12-14 | $15.96 | $16.23 | $15.87 | $16.19 | 1 945 809 |
| 2022-12-13 | $16.32 | $16.47 | $16.02 | $16.05 | 2 221 282 |
| 2022-12-12 | $15.70 | $16.11 | $15.66 | $16.08 | 2 975 169 |
| 2022-12-09 | $16.38 | $16.42 | $15.69 | $15.77 | 2 574 751 |
| 2022-12-08 | $16.35 | $16.61 | $16.08 | $16.52 | 1 334 777 |
| 2022-12-07 | $16.66 | $16.77 | $16.16 | $16.35 | 1 848 261 |
| 2022-12-06 | $17.32 | $17.67 | $16.54 | $16.67 | 1 348 729 |
| 2022-12-05 | $17.40 | $17.48 | $16.97 | $17.22 | 1 645 873 |
| 2022-12-02 | $16.92 | $17.51 | $16.85 | $17.39 | 1 719 228 |
| 2022-12-01 | $17.11 | $17.23 | $16.85 | $17.04 | 1 824 151 |
| 2022-11-30 | $16.53 | $17.10 | $16.53 | $17.08 | 2 331 122 |
| 2022-11-29 | $16.68 | $16.77 | $16.38 | $16.44 | 1 501 277 |
| 2022-11-28 | $16.88 | $16.97 | $16.69 | $16.79 | 1 764 503 |
| 2022-11-25 | $16.80 | $16.96 | $16.78 | $16.94 | 485 040 |
| 2022-11-23 | $17.16 | $17.40 | $16.85 | $16.86 | 986 165 |
| 2022-11-22 | $16.80 | $17.13 | $16.72 | $17.12 | 1 535 178 |
| 2022-11-21 | $16.94 | $17.01 | $16.81 | $16.82 | 661 449 |
| 2022-11-18 | $17.04 | $17.07 | $16.67 | $16.82 | 760 718 |
| 2022-11-17 | $16.72 | $16.99 | $16.71 | $16.86 | 770 093 |
| 2022-11-16 | $16.93 | $16.97 | $16.64 | $16.88 | 1 058 541 |
| 2022-11-15 | $16.99 | $17.18 | $16.79 | $16.87 | 1 192 186 |
About Exelixis
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CA... EXEL Profile
Top Fintech Company
featured in The Global Fintech Index 2020 as the top Fintech company of the country.
